Claims for Patent: 7,608,756

Summary for Patent: 7,608,756

Title:	Promoters for epidermis-specific expression of desired coding sequences in transgenic plants
Abstract:	The invention relates to methods of producing transgenic plants including pathogen resistant plants with recombinant nucleic acid molecules comprising promoter regions which provides expression of a desired transgene in epidermis-specific manner, and transgenic plants produced by said methods.
Inventor(s):	Schweizer; Patrick (Ballenstedt, DE), Dudler; Robert (Uster, CH), Schulze-Lefert; Paul (Koln, DE), Panstruga; Ralph (Aachen, DE)
Assignee:	IPK Institut fur Pflanzengenetik und Kulturpflanzenforschung (Gatersleben, DE) Max-Planck-Gesellschaft zur Forderung der Wissenschaften E.V. (Munchen, DE) Universitat Zurich (Zurich, CH)
Application Number:	10/574,740
Patent Claims:	1. A method of causing epidermis specific expression of a desired coding sequence in a transgenic plant, the method comprising introducing into a plant cell a chimeric gene comprising an isolated promoter region that controls epidermis-specific expression operably linked to the desired coding sequence, said promoter region comprising a first sequence originating from the promoter of a GSTA1 gene and a second sequence originating from the intron of a WIR1a gene, wherein the first sequence is SEQ ID No. 1 and the second sequence is SEQ ID No. 2 or wherein the first sequence has at least 95% sequence identity to SEQ ID No. 1 and the second sequence has at least 95% sequence identity to SEQ ID No. 2. 2. A method for increasing pathogen resistance in a plant, the method comprising transforming a plant cell with a chimeric gene comprising an isolated promoter region that controls epidermis-specific expression operably linked to a DNA encoding a protein that confers pathogen resistance, said promoter region comprising a first sequence originating from the promoter of a GSTA1 gene and a second sequence originating from the intron of a WIR1a gene, wherein the first sequence is SEQ ID No. 1 and the second sequence is SEQ ID No. 2 or wherein the first sequence has at least 95% sequence identity to SEQ ID No. 1 and the second sequence has at least 95% sequence identity to SEQ ID No. 2; and regenerating a transformed plant from the transformed plant cell; said transformed plant exhibits increased resistance to a pathogen. 3. The method according to claim 1, wherein the first sequence is SEQ ID No. 1 and the second sequence is SEQ ID No. 2. 4. The method according to claim 2, wherein the first sequence is SEQ ID No. 1 and the second sequence is SEQ ID No. 2. 5. The method according to claim 1, wherein said isolated promoter region comprises the nucleic acid sequence of SEQ ID NO. 3, or has at least 95% sequence identity to the nucleic acid sequence of SEQ ID No. 3. 6. The method according to claim 2, wherein said isolated promoter region comprises the nucleic acid sequence of SEQ ID NO. 3, or has at least 95% sequence identity to the nucleic acid sequence of SEQ ID No. 3. 7. The method according to claim 1, wherein the desired coding sequence originates from a resistance gene. 8. The method according to claim 7, wherein the coding sequence encodes a peroxidase or an oxalate oxidase. 9. The method of claim 1, wherein the coding sequence is in antisense orientation. 10. A transgenic plant produced by the method of claim 1. 11. A transgenic plant produced by the method of claim 2. 12. The transgenic plant of claim 10, wherein said plant is a monocot or dicot plant. 13. The transgenic plant of claim 11, wherein said plant is a monocot or dicot plant. 14. The transgenic plant according to claim 12, wherein said plant is poaceae. 15. The transgenic plant according to claim 13, wherein said plant is poaceae. 16. The transgenic plant according to claim 14, wherein said plant is wheat or barley. 17. The transgenic plant according to claim 15, wherein said plant is wheat or barley.

Details for Patent 7,608,756

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2023-10-07
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2023-10-07
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2023-10-07